eurofins | Clinical Diagnostics

Eurofins Clinical Diagnostics UK Launch pTau181 Blood Test to Rule Out Alzheimer's Associated Amyloid Pathology

Eurofins Clinical Diagnostics UK have released the pTau181 test to rule out the Alzheimer's associated amyloid pathology.

With dementia affecting almost 1 million people in the UK, Alzheimer's disease accounts for 60-80% of cases, access to this new test will streamline the clinical approach to Alzheimer's disease diagnosis and patient care.

pTau181 is targeted for use during the assessment of patients with cognitive decline before the onset of Alzheimer's disease symptoms.

pTau181 is a minimally invasive blood test with a high negative predictive value of ~94% to rule out Alzheimer's amyloid pathology, making it a valuable test for healthcare professionals. Positive results should form part of wider analysis and diagnosis of Alzheimer's disease in conjunction with other clinical information and further investigative testing such as CSF and PET scans.

Over **1 million** people in the UK have dementia

Alzheimer's accounts for **60-80%** of cases

pTau181 is a simple rule out blood test

Available from Eurofins Clinical Diagnostics in the UK, pTau181 is aimed at patients aged 55 to 80 years old with subjective cognitive decline, non-specific cognitive impairment, or suspected mild cognitive impairment (MCI) and for patients undergoing evaluation for Alzheimer's disease where amyloid pathology needs to be ruled out early.

With a rapid turnaround time, patients can be directed to the most appropriate clinical pathway faster, aiding diagnosis and helping improve quality of life.

For further information please contact Eurofins Clinical Diagnostics UK:
enquiries@ctuk.eurofins.com

February 2026

Eurofins Clinical Diagnostics UK Limited
90 Priestley Road, Surrey Research Park, Guildford, Surrey GU2 7AU
01483 450388 | enquiries@ctuk.eurofins.com
www.eurofins.co.uk/clinical-diagnostics